122 related articles for article (PubMed ID: 11374802)
21. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
22. Small cell carcinoma of the uterine cervix--an uncommon variant of cervical cancer with neuroendocrine features.
Lenczewski A; Terlikowski S; Sulkowska M; Famulski W; Kisielewski W; Kulikowski M
Folia Histochem Cytobiol; 2001; 39 Suppl 2():89-90. PubMed ID: 11820641
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical expression patterns of S100, synaptophysin, chromogranin A and neuron specific enolase in predicting malignant behaviour in paragangliomas.
Nastos C; Yiallourou A; Kotsis T; Mizamtsidi M; Delaportas D; Kondi-Pafiti A; Polymeneas G
J BUON; 2018; 23(5):1540-1545. PubMed ID: 30570883
[TBL] [Abstract][Full Text] [Related]
24. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
25. Chromogranin A gene expression in non-small cell lung carcinomas.
Abbona G; Papotti M; Viberti L; Macrĭ L; Stella A; Bussolati G
J Pathol; 1998 Oct; 186(2):151-6. PubMed ID: 9924430
[TBL] [Abstract][Full Text] [Related]
26. Prognostic importance of neuroendocrine differentiation in Japanese breast cancer patients.
Sawaki M; Yokoi K; Nagasaka T; Watanabe R; Kagawa C; Takada H; Sato S; Yamada T; Kikumori T; Imai T; Nakao A
Surg Today; 2010 Sep; 40(9):831-5. PubMed ID: 20740345
[TBL] [Abstract][Full Text] [Related]
27. Neuroendocrine-like differentiation in patients with pancreatic carcinoma.
Tezel E; Nagasaka T; Nomoto S; Sugimoto H; Nakao A
Cancer; 2000 Dec; 89(11):2230-6. PubMed ID: 11147593
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids.
Manfé AZ; Norberto L; Marchesini M; Lumachi F
In Vivo; 2011; 25(6):1027-9. PubMed ID: 22021701
[TBL] [Abstract][Full Text] [Related]
29. [Neuroendocrine carcinoma of breast: a study of tumor morphology and subtyping].
Gao LX; Liu G; Li L; Lin HY; Jin H; Cheng J; Jin ML; Ding HY
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):604-9. PubMed ID: 22177244
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical study of neuroendocrine differentiation in primary glandular lesions and tumors of the urinary bladder.
Bollito ER; Pacchioni D; Lopez-Beltran A; Volante M; Terrone C; Casetta G; Mari M; DePompa R; Cappia S; Papotti M
Anal Quant Cytol Histol; 2005 Aug; 27(4):218-24. PubMed ID: 16220833
[TBL] [Abstract][Full Text] [Related]
31. Detection of neuroendocrine feature about salivary adenoid cystic carcinoma.
Sun C; Zhong M; Wang Z; Wang Y
Chin J Dent Res; 1999 Dec; 2(3-4):65-7. PubMed ID: 10863420
[TBL] [Abstract][Full Text] [Related]
32. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India.
Rekhi B; Patil B; Deodhar KK; Maheshwari A; A Kerkar R; Gupta S; Tongaonkar HB; Shrivastava SK
Ann Diagn Pathol; 2013 Feb; 17(1):1-9. PubMed ID: 22534245
[TBL] [Abstract][Full Text] [Related]
33. Expression of neuroendocrine markers in non-small cell lung cancer.
Sørhaug S; Steinshamn S; Haaverstad R; Nordrum IS; Martinsen TC; Waldum HL
APMIS; 2007 Feb; 115(2):152-63. PubMed ID: 17295682
[TBL] [Abstract][Full Text] [Related]
34. Secretagogin is a novel marker for neuroendocrine differentiation.
Birkenkamp-Demtröder K; Wagner L; Brandt Sørensen F; Bording Astrup L; Gartner W; Scherübl H; Heine B; Christiansen P; Ørntoft TF
Neuroendocrinology; 2005; 82(2):121-38. PubMed ID: 16449819
[TBL] [Abstract][Full Text] [Related]
35. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.
Graziano SL; Tatum AH; Newman NB; Oler A; Kohman LJ; Veit LJ; Gamble GP; Coleman MJ; Barmada S; O'Lear S
Cancer Res; 1994 Jun; 54(11):2908-13. PubMed ID: 8187076
[TBL] [Abstract][Full Text] [Related]
36. [Usefulness of chromogranin A determination in the diagnosis of neuroendocrine neoplasia].
Militello C; Cannizzaro R; Pradella P; Volpin E; Spirch S; Buonadonna A; De Appollonia L; Rossi C; Sigon R; Cipresso S; Terranova O
Chir Ital; 1999; 51(1):45-51. PubMed ID: 10514916
[TBL] [Abstract][Full Text] [Related]
37. [Detection of neuroendocrine differentiation in NSCLC and its clinical significance].
Ouyang N; Chen G; Ding J
Zhonghua Jie He He Hu Xi Za Zhi; 2001 Feb; 24(2):90-2. PubMed ID: 11802946
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma.
Skov BG; Sørensen JB; Hirsch FR; Larsson LI; Hansen HH
Ann Oncol; 1991 May; 2(5):355-60. PubMed ID: 1954180
[TBL] [Abstract][Full Text] [Related]
39. Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A.
Lai M; Lü B; Xing X; Xu E; Ren G; Huang Q
Virchows Arch; 2006 Oct; 449(4):402-9. PubMed ID: 16955307
[TBL] [Abstract][Full Text] [Related]
40. Neuroendocrine differentiation in colorectal carcinomas: assessing its prognostic significance.
Atasoy P; Ensari A; Demirci S; Kurşun N
Tumori; 2003; 89(1):49-53. PubMed ID: 12729362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
